|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 1,081 adults without dementia (375 healthy subjects and 706 individuals with mild cognitive impairment) were recruited from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to test the influence of BDNF Val66Met polymorphism on cognitive impairment, brain structure atrophy, and change in the levels of CSF biomarkers.
|
30775992 |
2019 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Nevertheless, after adjusting for age and APOE ε4 status, Val66Met was not associated with AD in females (OR, 1.02; 95% CI, 0.94-1.11; P = .57).
|
28984138 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we review the role and relevance of the BDNF Val66Met polymorphism in neurodegenerative diseases, with particular emphasis on glaucoma, multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29896439 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BDNF Val66Met polymorphism should be considered as a potential moderator of clinical trial outcomes in current treatment and prevention trials in DIAD and sporadic AD.Ann Neurol 2018;84:424-435.
|
30014553 |
2018 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results suggest that the <i>BDNF</i> Val66Met polymorphism may play an important role in cognitive decline and could be considered as a target for novel AD therapeutics.
|
28468845 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
BDNF Val66Met in preclinical Alzheimer's disease is associated with short-term changes in episodic memory and hippocampal volume but not serum mBDNF.
|
28720165 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression.
|
27335045 |
2017 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Dose-dependent genotype effects of BDNF Val66Met polymorphism on default mode network in early stage Alzheimer's disease.
|
27494844 |
2016 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
SEE ROGAEVA AND SCHMITT-ULMS DOI101093/AWW201 FOR A SCIENTIFIC COMMENTARY ON THIS ARTICLE: The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease.
|
27521573 |
2016 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis confirmed the gender-related association between BDNF 196A/G polymorphism and AD risk, which may indicate a certain effect of female hormone on progression of the disease.
|
24279351 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Moreover, the plasma BDNF level did not differ significantly among the three BDNF Val66Met genotypic groups or between patients with A-MCI and those with AD.
|
24253237 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cross-sectional genetic association studies have reported equivocal results on the relationship between the brain-derived neurotrophic factor (BDNF) Val66Met and risk of Alzheimer's disease (AD).
|
24475133 |
2014 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism has previously been implicated in Alzheimer's disease (AD)-related cognitive impairment.
|
23769397 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, val66met polymorphism and BDNF serum level between the three groups and genotype did not significantly affect the serum BDNF level or age, Mini-Mental State Examination score in AD and aMCI.
|
23270505 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Understanding the role of brain-derived neurotrophic factor (BDNF) in synaptic plasticity and synaptogenesis, the impact of the BDNF Val66Met polymorphism in Alzheimer's disease-relevant endophenotypes - including episodic memory and hippocampal volume - and the technological progress in measuring synaptic changes in humans all pave the way for a 'synaptic repair' therapy for neurodegenerative diseases that targets pathophysiology rather than pathogenesis.
|
23674053 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the possible relationship between genetic risk factors and depression in AD, we assessed genetic polymorphisms reported to be associated with depression (MAOA VNTR, ACE 288bp Insertion/ Deletion, 5HTTLPR, COMT Val158Met, BDNF Val66Met, TPH1 A218C, HTR2A T102C, P2RX7 Q460R, FKBP5 rs1360780 and CRHR1 rs242941) in a cross-sectional study on 246 AD patients with or without clinically significant major depressive disorder (MDD) according to DSM-IV.
|
23157339 |
2013 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among 200 outpatients with dementia and MCI, 146 outpatients with mild AD or A-MCI were recruited and divided into two genotypic groups, valine homozygosity (Val/Val) and methionine (Met) carriers, based on the representative BDNF functional polymorphism Val66Met.
|
22699449 |
2012 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
The current study examined potential association between single nucleotide polymorphisms (SNPs) of the BDNF gene (G11757 C, C270T, G196A, G-712A) and Alzheimer's disease-related depression (AD-D).
|
21677379 |
2011 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
The gene variants of the BDNF Val66Met polymorphism were significantly associated with the presence of psychotic symptoms in male, but not in female patients with AD.
|
21044653 |
2011 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
One hundred and sixty-nine outpatients with AD or amnestic mild cognitive impairment (A-MCI) were recruited to the study and divided into three genotypic groups for each representative BDNF functional polymorphism as follows: (i) Val66Met (G196A): G/G (n = 45), G/A (n = 104), and A/A (n = 20); and (ii) C270T: C/C (n = 160), C/T (n = 9), and T/T (n = 0).
|
21951954 |
2011 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
To determine whether the BDNF Val66Met gene variant interacts with age to predict brain and cognitive measures in healthy volunteers across the adult lifespan in an intermediate phenotype pattern related to AD by examining (1) cortical thickness, (2) fractional anisotropy of white matter tracts (ie, white matter integrity), and (3) episodic memory performance.
|
21300947 |
2011 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although Val66Met polymorphisms were not associated with the cross-sectional diagnoses of MCI or AD, the presence of Met-BDNF allele was associated with a higher risk of disease-progression in patients with MCI (OR=3.0 CI(95%) [1.2-7.8], P=0.02).
|
20491609 |
2010 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease.
|
19812463 |
2010 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease.
|
20613678 |
2010 |
|
Alzheimer's Disease
|
|
0.100 |
GeneticVariation
|
BEFREE |
A single nucleotide polymorphism in the human BDNF gene (Val66Met) affects memory, and influences Alzheimer's disease and depression vulnerability in a sex-specific manner.
|
20097294 |
2010 |